Reviva Pharmaceuticals announces grant of European patent for brilaroxazine

Reviva Pharmaceuticals (RVPH) announced European Patent 3749324 has been granted by the European Patent Office covering use of brilaroxazine for the treatment of pulmonary fibrosis, including idiopathic pulmonary fibrosis, adding to its existing patent protection in key markets around the world including the United States, China and Japan. Brilaroxazine has received Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of IPF. “Securing this latest patent further strengthens our intellectual property portfolio and underscores the broad therapeutic relevance of brilaroxazine’s unique mechanism of action in chronic fibrotic disorders like pulmonary fibrosis or IPF,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO. “With a late-stage asset that in our trials has been well-tolerated across large patient populations, we are poised to further expand clinical development from schizophrenia into additional high-value indications with the potential for multiple paths to value creation for our brilaroxazine program.”